Castrate Resistent Prostate Cancer
Conditions
Keywords
metastatic, castration resistant prostate cancer, Therapeutic Vaccine, Dendritic cell, BPX-201, BPX201, AP1903
Brief summary
This is a Phase I, non-randomized, dose escalation study of the safety, biomarkers, and preliminary efficacy of dendritic cell vaccine, BPX-201, plus activating agent, AP1903, in patients with metastatic castrate resistant prostate cancer.
Detailed description
This is a Phase I study of therapeutic vaccine, BPX-201, plus activating agent, AP1903, in patients with mCRPC. Patients will be screened within 8 weeks prior to first vaccine administration (4 weeks prior to leukapheresis). The trial design consists of 3 cohorts of 6 patients each, receiving escalating doses of BPX-201 of 10 million (M), 20M and 40M cells, respectively. Dose escalation will occur according to a 3+3 design. Patients will receive administration of BPX-201 every other week for 6 cycles (1 cycle equals 2 weeks). Approximately 1.6 mL of BPX-201 will be administered as 8 intradermal injections (200μL each) at each treatment visit. On the day following each vaccination, a single 40 mg dose of the activating agent, AP1903, will be administered via intravenous (IV) infusion over 2 hours.
Interventions
BIOLOGICALBPX-201 vaccine plus AP1903
The trial design consists of 3 cohorts of 6 patients each, receiving escalating doses of BPX-201 of 10 million (M), 20M and 40M cells, respectively. Dose escalation will occur according to a 3+3 design. Patients will receive administration of BPX-201 every other week for 6 cycles (1 cycle equals 2 weeks). Approximately 1.6 mL of BPX-201 will be administered as 8 intradermal injections (200μL each) at each treatment visit. On the day following each vaccination, a single 40 mg dose of the activating agent, AP1903, will be administered via intravenous (IV) infusion over 2 hours.
Sponsors
Bellicum Pharmaceuticals
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Written informed consent 2. 18 years of age or older 3. Histologically confirmed, metastatic prostate cancer (positive bone scan and/or measurable disease on CT scan and/or MRI of the abdomen and pelvis). 4. Progressive disease after androgen deprivation, as defined by Prostate Cancer Working Group 2 and/or Response Evaluation Criteria in Solid Tumors criteria 5. Laboratory requirements: * Absolute neutrophil count (ANC) ≥ 1500/μL * Bilirubin \< 1.5 x ULN * Hemoglobin \> 8 g/dL * PSA \> 2 ng/mL * Platelets \> 100,000/µL * AST and ALT \< 2.5 x ULN * Creatinine clearance ≥ 60mL/min * Testosterone \< 50 ng/dL 6. Eastern Cooperative Oncology Group (ECOG) performance status 0 - 2 and life expectancy \> 12 weeks 7. Patients receiving any other hormonal therapy, including any dose of megestrol acetate (Megace), Proscar (finasteride), any herbal product known to decrease PSA levels (e.g. Saw Palmetto, PC-SPES), or agents such as abiraterone, TAK700, MDV3100 as well as any systemic corticosteroid use, must discontinue the agent for at least four weeks prior to study treatment. Progressive disease as defined above must be documented after discontinuation of any hormonal therapy (with the exception of a LHRH agonist). 8. Prior radiation therapy must be completed \> 4 weeks prior to enrollment and the patient must have recovered from all toxicity. Prior radiopharmaceuticals (strontium, samarium) must be completed ≥ 8 weeks prior to enrollment. 9. Because of the unknown potential risk to a gamete and/or developing embryo from these investigational therapies, patients must agree to use adequate contraception (barrier method for males) for the duration of study participation, and for three months after discontinuing therapy.
Exclusion criteria
1. Prior chemotherapy for prostate cancer, with the exception of neo-adjuvant chemotherapy, because of the potential effect of chemotherapy on the immune system. 2. Prior sipuleucel-T treatment or investigational immunotherapy. 3. Prostate cancer pain requiring regularly scheduled narcotics. 4. Current treatment with systemic steroid therapy (inhaled/topical steroids are acceptable). Systemic corticosteroids must be discontinued for at least 4 weeks prior to first treatment. 5. Clinically active autoimmune disease. 6. Diagnosis of prostate cancer with neuroendocrine differentiation 7. Known presence of central nervous system metastases, pleural effusions or ascites 8. Medical or psychiatric illness that would, in the opinion of the investigator, preclude participation in the study or the ability of patients to provide informed consent for themselves. 9. Cardiovascular disease that meets one of the following: congestive heart failure (New York Heart Association Class III or IV), active angina pectoris, or recent myocardial infarction (within the last 6 months). 10. Concurrent or prior malignancy except for the following: * Adequately treated basal or squamous cell skin cancer * Adequately treated stage I or II cancer from which the patient is currently in complete remission * Any other cancer from which the patient has been disease-free for 5 years 11. Known HIV or other history of immunodeficiency disorder. 12. Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or medical (e.g. infectious) illness. 13. Any underlying medical or psychiatric condition, which in the opinion of the investigator will make the administration of BPX-201 and AP1903 hazardous or obscure the interpretation of AEs, such as a condition associated with frequent diarrhea. 14. Any non-oncology vaccine therapy used for prevention of infectious diseases for up to 1 month before BPX-201
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants with adverse events as a measure of safety and tolerability | 2 years | Safety will be measured through the monitoring of AEs, clinical laboratory parameters (hematology, serum chemistry, and urinalysis), vital sign measurements, and physical examinations. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| prostatic specific antigen | 3 months | Measure PSA response and PSA doubling time as measured from PSA nadir through 12 weeks |
| Progression free survival | 2 years | Rate of PFS |
| Reduction in circulating tumor cells | 2 years | Change from baseline in number of circulating tumor cells |
| Response to chemotherapy after vaccine | 2 years | Response to chemotherapy upon progression |
Countries
United States
Outcome results
None listed